Rachel Diamant

Rachel Diamant co-founded EmendoBio and serves as Chief Business Officer. In her role as CBO, Rachel builds EmendoBio’s pipeline of therapeutic programs, as well as oversees academic and industrial collaborations and partnerships for the development of selected indications and genomic targets. She is also responsible for EmendoBio’s IP strategy. Rachel has been a consultant for numerous biotechnology and medical device companies and accumulated extensive expertise in IP mining, strategic portfolio design and hands-on portfolio management. Rachel holds an M.Sc. in Neurobiology from the Weizmann Institute of Science and a Biotechnology Engineering degree from the Technion Israel Institute of Technology.